= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Nicolas

MSACL 2018 EU Abstract

Topic: Microbiology

Podium Presentation in the Ether on Wednesday at 11:20 (Chair: Simon Cameron)

Characterization of the Virulome of Staphylococcus Aureus by a Highly Multiplex Approach with Scout-MRM

Mouton Nicolas (Presenter)
University de Lyon Claude Bernard

Authors: Nicolas Mouton (1), Mariane Pivard (2), Romain Carrière (1), Sophie Ayciriex (1), Florence Couzon (2), Karen Moreau (2), Fabien Chirot (1), Francois Vandenesch (2), and Jerôme Lemoine (1).
(1) Institut des Sciences Analytiques (ISA), Ecole Normale Supérieure - Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Centre National de la Recherche Scientifique/ UMR5280 - 5 rue de la Doua, 69100 Villeurbanne, France (2) Centre International de Recherche en Infectiologie (CIRI), Universite Claude Bernard - Lyon I, Inserm : U1111, Faculté de médecine Lyon Est - Site Laennec - 7 rue Guillaume Paradin 69372 Lyon Cedex 08, France

Abstract

The emergence of antibiotic-resistant bacteria strains is seriously threatening human life, as recently underlined by the World Health Organization. The case of Staphylococcus aureus, S.a. is of particular concern, whose forms resisting to vancomycin or methicillin caused numerous patients death in Hospitals. It is also crucial to better understand how mutations of the bacterial genome induce the emergence of new resistant strains. The sensitivity and multiplexing possibilities of mass spectrometric (MS) approaches appears particularly relevant to tackle such problems. We thus developed a targeted assay covering 90 key proteins involved in S.a. virulence and antibiotic resistance using a novel and a highly multiplexed targeted-MS approach, Scout-MRM. The virulome assay has been implemented for deciphering the proteogenomic links across a clinical collection of 230 S.a. strains.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no